This product is a CRISPR/Cas9-edited polyclonal knockout cell population harboring targeted disruption of the human BBC3 gene (PUMA) in the 769-P epithelial cell line. The polyclonal pool comprises a heterogeneous edited cell mixture, providing a loss-of-function model without clonal isolation, suitable for studying BBC3-dependent apoptotic signaling.
The 769-P cell line originates from a human clear cell renal cell adenocarcinoma, serving as a well-characterized model of renal cell carcinoma (RCC). These epithelial cells retain key oncogenic features and aberrant apoptotic regulation, including altered BH3-only protein expression. BBC3 knockout in this background enables dissection of PUMA-mediated apoptosis in a clinically relevant RCC context.
BBC3 is a critical BH3-only pro-apoptotic protein activated downstream of TP53, E2F1, and FOXO3a in response to DNA damage, hypoxia, and cellular stress. Upon induction, BBC3 binds and inhibits anti-apoptotic BCL2 family members??primarily BCL2, BCLXL, and MCL1??liberating BAX and BAK to drive mitochondrial outer membrane permeabilization (MOMP), cytochrome c release, APAF1 apoptosome assembly, and caspase cascade activation. This knockout model disrupts the intrinsic apoptosis pathway at the level of pro-apoptotic signaling initiation.
In RCC, BBC3 is frequently implicated in therapy-induced apoptosis and drug resistance, particularly under hypoxic conditions common in clear cell tumors. The 769-P BBC3 knockout cells allow investigation of how PUMA loss affects responses to chemotherapeutics, targeted agents, and radiation. This model facilitates elucidation of compensatory survival mechanisms and validation of downstream apoptotic effectors in epithelial cancer.
Experimental applications encompass annexin V and caspase-3/7 activity assays for apoptosis quantification, western blotting for BCL2 family and caspase cleavage profiling, co-immunoprecipitation to assess protein?Cprotein interactions, and mitochondrial membrane potential assays (e.g., JC-1) to evaluate MOMP. Cell viability assays further enable drug sensitivity profiling. This product is ideal for studies in renal cancer biology, DNA damage response, and apoptosis signaling. For technical support, contact Ascent Research.
